nach oben

Breast Cancer Research and Treatment

Erschienen in:

22.01.2021 | Review

Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review

verfasst von: Lua Jafari, Nausheen Akhter

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cardiotoxicity from anti-human epidermal growth factor receptor 2 (HER2) therapy carries a short- and long-term risk of incident heart failure and increased cardiovascular mortality in patients with breast cancer. Interruptions in anti-HER2 therapy due to cardiotoxicity can lead to suboptimal cancer treatment. The purpose of this narrative review is to outline opportunities to optimize cardiovascular care in patients with HER2-positive breast cancer to prevent interruptions in therapy.

Methods

This case-based review presents the current literature on evidence-based strategies for personalized cardiotoxicity risk assessment, risk mitigation interventions, cardiac function surveillance tools, and management of asymptomatic left ventricular dysfunction in breast cancer patients receiving anti-HER2 therapy.

Results

Pretreatment cardiac risk assessment incorporates both treatment-related risk factors and patient-related risk factors for the development of cardiac dysfunction. Prevention and monitoring strategies while on treatment utilize risk factor modification, imaging and biomarker surveillance. Management of asymptomatic left ventricular dysfunction due to anti-HER2 therapy is evolving. Permissive cardiotoxicity in asymptomatic patients while starting cardioprotective therapies requires close collaboration between oncology and cardiology, and referral to cardio-oncology if available.

Conclusions

Patient-centered, multimodal strategies to prevent, detect, and manage cardiotoxicity from anti-HER2 therapy are necessary to improve outcomes in patients with HER2-positive breast cancer.

Miller KD, Nogueira L, Mariotto AB et al (2019) Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 69(5):363–385PubMed

Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30CrossRefPubMed

DeSantis CE, Ma J, Gaudet MM et al (2019) Breast cancer statistics, 2019. CA Cancer J Clin 69(6):438–451PubMed

Benjamin EJ, Muntner P, Alonso A et al (2019) Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation 139(10):e56–e528PubMed

Mehta LS, Watson KE, Barac A et al (2018) Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation 137(8):e30–e66PubMedPubMedCentral

Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD (2016) Cardiovascular Disease Mortality Among Breast Cancer Survivors. Epidemiology 27(1):6–13PubMedPubMedCentral

Abdel-Qadir H, Austin PC, Lee DS et al (2017) A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer. JAMA Cardiol 2(1):88–93PubMed

Herrmann J (2020) Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. https://doi.org/10.1038/s41569-020-0348-1CrossRefPubMedPubMedCentral

Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22(4):263–302PubMed

10.

Banke A, Fosbol EL, Ewertz M et al (2019) Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab. JACC Heart Fail 7(3):217–224PubMed

11.

Drullinsky PR, Hurvitz SA (2020) Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. Breast Cancer Res Treat 181(2):233–248PubMed

12.

Yu AF, Yadav NU, Lung BY et al (2015) Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat 149(2):489–495PubMedPubMedCentral

13.

Copeland-Halperin R, Al-Sadawi M, Patil S et al (2020) The Impact of Cardiotoxicity and Trastuzumab Interruption on Breast Cancer Outcomes. J Am Coll Cardiol 75(11):741

14.

Armenian SH, Lacchetti C, Barac A et al (2017) Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35(8):893–911PubMed

15.

Curigliano G, Lenihan D, Fradley M et al (2020) Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 31(2):171–190PubMed

16.

Zamorano JL, Lancellotti P, Rodriguez Munoz D et al (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37(36):2768–2801PubMed

17.

Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M (2014) Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc 89(9):1287–1306PubMed

18.

Lyon AR, Dent S, Stanway S et al (2020) Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 22(11):1945–1960PubMed

19.

Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England journal of medicine 353(16):1673–1684PubMed

20.

Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. The New England journal of medicine 365(14):1273–1283PubMedPubMedCentral

21.

Smith I, Procter M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (London, England) 369(9555):29–36

22.

Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23(13):2900–2902

23.

Hudis CA (2007) Trastuzumab–mechanism of action and use in clinical practice. The New England journal of medicine 357(1):39–51PubMed

24.

Lemmens K, Doggen K, De Keulenaer GW (2007) Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 116(8):954–960PubMed

25.

Keefe DL (2002) Trastuzumab-associated cardiotoxicity. Cancer 95(7):1592–1600PubMed

26.

Telli ML, Witteles RM (2011) Trastuzumab-related cardiac dysfunction. J Natl Compr Canc Netw 9(2):243–249PubMed

27.

Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792PubMed

28.

Romond EH, Jeong JH, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30(31):3792–3799PubMedPubMedCentral

29.

Perez EA, Suman VJ, Davidson NE et al (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26(8):1231–1238PubMed

30.

Goel S, Liu J, Guo H et al (2019) Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. JACC Heart Fail 7(9):795–804PubMed

31.

de Azambuja E, Procter MJ, van Veldhuisen DJ et al (2014) Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1–01). J Clin Oncol 32(20):2159–2165PubMed

32.

Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. N Engl J Med 355(26):2733–2743PubMed

33.

Baselga J, Cortés J, Kim S-B et al (2011) Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med 366(2):109–119PubMedPubMedCentral

34.

Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf. Revised October 2019. Accessed January 2, 2021.

35.

Thavendiranathan P, Abdel-Qadir H, Fischer HD et al (2016) Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study. J Clin Oncol 34(19):2239–2246PubMed

36.

Genentech, Inc. Herceptin Hylecta [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761106s000lbl.pdf. Revised February 2019. Accessed January 2, 2021.

37.

Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125409lbl.pdf. Revised June 2012. Accessed January 2, 2021.

38.

MacroGenics, Inc. Margenza (margetuximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed January 2, 2021.

39.

Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125427s105lbl.pdf. Revised May 2019. Accessed January 2, 2021. .

40.

Daiichi Sankyo, Inc. Enhertu (fam-trastuzumab deruxtecan-nxki) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf. Revised December 2019. Accessed January 2, 2021.

41.

GlaxoSmithKline. Tykerb (Lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022059lbl.pdf. Revised March 2007. Accessed January 2, 2021.

42.

Puma Biotechnology, Inc. Nerlynx (Neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf. Revised July 2017. Accessed January 2, 2021.

43.

Seattle Genetics, Inc. Tukysa (Tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf. Revised April 2020. Accessed January 2, 2021.

44.

Ezaz G, Long JB, Gross CP, Chen J (2014) Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 3(1):e000472PubMedPubMedCentral

45.

Abdel-Qadir H, Thavendiranathan P, Austin PC et al (2019) Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study. Eur Heart J 40(48):3913–3920PubMed

46.

Whelton PK, Carey RM, Aronow WS et al (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71(19):2199–2269PubMed

47.

Pituskin E, Mackey JR, Koshman S et al (2017) Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol 35(8):870–877PubMed

48.

Guglin M, Krischer J, Tamura R et al (2019) Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol 73(22):2859–2868PubMedPubMedCentral

49.

Vaduganathan M, Hirji SA, Qamar A et al (2019) Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy. J Am Coll Cardiol CardioOnc 1(1):54–65

50.

Grundy SM, Stone NJ, Bailey AL et al (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139(25):e1082–e1143PubMed

51.

Yin AB, Brewster AM, Barac A, Thoman W, Oeffinger K, Gilchrist SC (2019) Cardiovascular Prevention Strategies in Breast Cancer. J Am Coll Cardiol CardioOnc 1(2):322–325

52.

Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH (2012) Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol 60(23):2384–2390PubMed

53.

Acar Z, Kale A, Turgut M et al (2011) Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol 58(9):988–989PubMed

54.

U.S. National Institutes of Health, National Library of Medicine, ClinicalTrials.gov. Preventing anthracycline cardiovascular toxicity with statins (PREVENT). https://clinicaltrials.gov/ct2/show/NCT01988571. Accessed 19th July 2020.

55.

Jones LW, Habel LA, Weltzien E et al (2016) Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer. J Clin Oncol 34(23):2743–2749PubMedPubMedCentral

56.

Gilchrist SC, Barac A, Ades PA et al (2019) Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. Circulation 139(21):e997–e1012PubMedPubMedCentral

57.

Yu AF, Moskowitz CS, Lee Chuy K et al (2020) Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy. J Am Coll Cardiol CardioOnc 2(2):166–175

58.

de Azambuja E, Trapani D, Loibl S et al (2020) ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. ESMO Open. https://doi.org/10.1136/esmoopen-2020-000826CrossRefPubMedPubMedCentral

59.

Fallah-Rad N, Walker JR, Wassef A et al (2011) The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 57(22):2263–2270PubMed

60.

Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH (2014) Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 15(3):324–331PubMed

61.

Sawaya H, Sebag IA, Plana JC et al (2012) Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5(5):596–603PubMedPubMedCentral

62.

Negishi T, Thavendiranathan P, Negishi K, Marwick TH, Investigators S (2018) Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial. JACC Cardiovasc Imaging. 11(8):1098–1105PubMed

63.

Thavendiranathan P, Negishi T, Somerset E et al (2020) Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2020.11.020CrossRefPubMedPubMedCentral

64.

Cardinale D, Colombo A, Torrisi R et al (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28(25):3910–3916PubMed

65.

Zardavas D, Suter TM, Van Veldhuisen DJ et al (2017) Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. J Clin Oncol 35(8):878–884PubMed

66.

Plana JC, Galderisi M, Barac A et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27(9):911–939PubMed

67.

Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147-239PubMed

68.

Yancy CW, Jessup M, Bozkurt B et al (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail 23(8):628–651PubMed

69.

Hussain Y, Drill E, Dang CT, Liu JE, Steingart RM, Yu AF (2019) Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction. Breast Cancer Res Treat 175(1):239–246PubMedPubMedCentral

70.

Leong DP, Cosman T, Alhussein MM et al (2019) Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity. J Am Coll Cardiol CardioOnc 1(1):1–10

71.

Lynce F, Barac A, Geng X et al (2019) Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat 175(3):595–603PubMedPubMedCentral

Titel: Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review
verfasst von: Lua Jafari
Nausheen Akhter
Publikationsdatum: 22.01.2021
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2021
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-021-06096-9

Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials

Open Access
Clinical trial

Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells

Preclinical study

Meta-analysis and cost-effectiveness of ductoscopy, duct excision surgery and MRI for the diagnosis and treatment of patients with pathological nipple discharge

Open Access
Review

Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series

Open Access
Brief Report

COVID-19 and breast cancer at a Regional Breast Centre: our flexible approach during the pandemic

Zur Zeit gratis
COVID-19
Epidemiology

Prediction of axillary nodal burden in patients with invasive lobular carcinoma using MRI

Clinical trial

Neu im Fachgebiet Onkologie

Krebsscreeningprogramme erreichen Menschen mit kognitiver Beeinträchtigung schlechter

14.03.2025
Früherkennungsuntersuchung
Nachrichten

Daten aus den Niederlanden zeigen, dass Krebsfrüherkennungsmaßnahmen für Menschen mit Störungen der Intelligenzentwicklung häufig nicht zugänglich sind. Wie kann diese Lücke geschlossen werden?

Perkutane Ablation – ungenutztes Potenzial für die Schmerztherapie?

12.03.2025
Tumorschmerz
Nachrichten

Geht es nach US-Versicherungsdaten, ist die perkutane Ablation eine vorteilhafte, aber zu selten genutzte Option in der Schmerzlinderung von Personen mit bestimmten Tumoren. Wichtige Fragen bleiben allerdings unbeantwortet.

Reduzieren Kälte und Kompression die CIPN-Gefahr in den Händen?

12.03.2025
Nebenwirkungen der Krebstherapie
Nachrichten

Ergebnisse der deutschen POLAR-Studie sprechen dafür, dass kühlende oder komprimierende Handschuhe das Risiko für eine Taxan-induzierte periphere Neuropathie senken können. Ein paar Fragen bleiben aber offen.

BCG-Therapie kann die Zystektomie ersparen

11.03.2025
Harnblasenkarzinom
Nachrichten

Patienten und Patientinnen mit hoch- oder äußerst riskantem nicht muskelinvasivem Blasenkrebs können mithilfe von BCG-Instillationen die radikale Zystektomie mitunter vermeiden. Muss die Blase später doch entfernt werden, darf der rechte Zeitpunkt nicht verpasst werden.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review

Abstract

Purpose

Methods

Results

Conclusions

Weitere Artikel der Ausgabe 2/2021

Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials

Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells

Meta-analysis and cost-effectiveness of ductoscopy, duct excision surgery and MRI for the diagnosis and treatment of patients with pathological nipple discharge

Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series

COVID-19 and breast cancer at a Regional Breast Centre: our flexible approach during the pandemic

Prediction of axillary nodal burden in patients with invasive lobular carcinoma using MRI

Neu im Fachgebiet Onkologie

Krebsscreeningprogramme erreichen Menschen mit kognitiver Beeinträchtigung schlechter

Perkutane Ablation – ungenutztes Potenzial für die Schmerztherapie?

Reduzieren Kälte und Kompression die CIPN-Gefahr in den Händen?

BCG-Therapie kann die Zystektomie ersparen

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten